Initial results with oral administration of ICI 204,219.
Glass
M
M
ICI Pharmaceuticals Group, ICI Americas, Wilmington, Delaware 19897.
D000284:Administration, Oral; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists; D008168:Lung / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D048448:Phenylcarbamates; D013189:SRS-A / Q000494:pharmacology; D012867:Skin / Q000187:drug effects; D012879:Skin Physiological Phenomena; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013189:SRS-A; D013449:Sulfonamides; D014105:Tosyl Compounds; C062735:zafirlukast